Polycystic Ovary Syndrome Health-related Quality of Life
Conditions
Keywords
polycystic ovary syndrome, PCOS, quality of life, health-related quality of life, mPCOSQ, questionnaire, SF-36, French
Brief summary
This study is a prospective, observational, bicentric study, evaluating the validity and reliability of a French version of the mPCOSQ questionnaire (mPCOSQ-F), used to assess health-related quality of life (HRQOL) in women with polycystic ovary syndrome. The first stage of the study consisted in translating the questionnaire from English to French. Patients agreeing to take part in the study will complete the mPCOSQ-F and the SF-36 (generic HRQOL questionnaire). After 1 to 2 weeks, patients will receive the mPCOSQ-F and complete it again.
Detailed description
The aim of this study is to assess the validity and reliability of a French version of the mPCOSQ questionnaire (mPCOSQ-F), used to assess health-related quality of life (HRQOL) in women with polycystic ovary syndrome. Women aged 18 to 45 years with a diagnosis of polycystic ovary syndrome will be included. The first stage of the study consisted in translating the questionnaire from English to French. Patients agreeing to take part in the study will complete the mPCOSQ-F and the SF-36 (generic HRQOL questionnaire). After 1 to 2 weeks, patients will receive the mPCOSQ-F and complete it again. The pre-test phase purpose is to appraise the face validity and feasibility of the questionnaire through phone interviews with the thirty first respondents. In the final phase, we aimed to evaluate the validity and reliability of the mPCOSQ, and to compare it to the SF-36.
Interventions
OTHERmPCOSQ-F and SF-36
Questionnaires
Sponsors
CHU de Reims
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No
Inclusion criteria
* Women aged 18 to 45 * Fluent in french * Having a diagnosis of PCOS according to the international recommendations published in 2023 * Willing to participate in the study * Affiliated to the french social security system
Exclusion criteria
* Diagnosis of adrenal hyperplasia, androgen-producing tumor, Cushing's syndrome, or thyroid disorder * Pregnancy or breast-feeding * Under legal protection
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Content validity of mPCOSQ as determined by the experts group | At 2 years |
| Feasibility of mPCOSQ | At 2 years |
| Acceptability of mPCOSQ | At 2 years |
| Structure validity of mPCOSQ | At 2 years |
| Reproductibility of mPCOSQ | At 2 years |
| Reliabilty of mPCOSQ | At 2 years |
| Total mPCSOQ score | At 15 days |
| SF-36 scores | At 1 day |
| Scores in the weight domain based on BMI | At 1 day |
| Scores in the fertility domain based on the need for reproductive medicine or parenthood | At 1 day |
| Scores in the hirsutism domain based on the Ferriman-Gallwey score | At 1 day |
Countries
France
Contacts
Primary ContactSara BARRAUD
Backup ContactCamille TETU
Outcome results
None listed